Drug intelligence / Profile preview

gimeracil

Development stage
Unknown
Lead developer
Taiho Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Gimeracil is a small molecule enzyme inhibitor used as an adjunct in antineoplastic therapy. Its primary role is to inhibit the enzyme dihydropyrimidine dehydrogenase (DPD), which is responsible for the degradation of fluorouracil (5-FU). By blocking DPD reversibly, gimeracil increases and prolongs systemic exposure to 5-FU when administered as part of oral chemotherapy regimens such as Teysuno or TS-1. This enhances the cytotoxic effect against cancer cells by maintaining higher concentrations of active drug. Gimeracil itself does not have direct antitumor activity but potentiates the efficacy and duration of action for fluoropyrimidine-based chemotherapies[1][2][3][6].

Brand names
Gimeracil (as an ingredient, not a standalone brand)Teysuno (as part of combination)TS-1 (as part of combination)S-1 (as part of combination)
Other names
5-chloro-2,4-dihydroxypyridine5-chloro-4-hydroxy-2(1H)-pyridinonegimestat5-chloro-pyridine 2,4-diolGIMERACIL [INN]GIMERACIL [JAN]
02

Targets

DPYD (Dihydropyrimidine dehydrogenase)

Beyond the preview

Go deeper on gimeracil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gimeracil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call